Pfizer Selects Final Two Targets in Hepatic Disease Partnership with Wave Life Sciences

Pfizer has selected the final two targets in a two-year-old, up-to-$911 million collaboration with Wave Life Sciences to develop new treatments for metabolic hepatic diseases, including nonalcoholic steatohepatitis (NASH), Wave said today.Pfizer has nominated the fourth and fifth targets of the collaboration, designed to apply Wave’s stereochemistry platform across antisense and single-stranded RNA interference (RNAi) modalities, along with the aminosugar N -acetylgalactosamine (GalNAc) an